Rallybio Corporation Common Stock is a biotechnology business based in the US. Rallybio Corporation Common Stock shares (RLYB) are listed on the NASDAQ and all prices are listed in US Dollars. Rallybio Corporation Common Stock employs 31 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $9.72 |
|---|---|
| 52-week range | $8.06 - $25.78 |
| 50-day moving average | $11.96 |
| 200-day moving average | $14.12 |
| Wall St. target price | $30.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-5.11 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $9.72 from 2022-01-20
| 1 week (2022-01-14) | 9.58% |
|---|---|
| 1 month (2021-12-21) | -9.67% |
| 3 months (2021-10-21) | -39.14% |
| 6 months (2021-07-17) | N/A |
| 1 year (2021-01-17) | N/A |
|---|---|
| 2 years (2020-01-17) | N/A |
| 3 years (2019-01-17) | N/A |
| 5 years (2017-01-17) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | 0% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | $5.80 |
| Market capitalisation | $278.9 million |
TTM: trailing 12 months
We're not expecting Rallybio Corporation Common Stock to pay a dividend over the next 12 months.
You may also wish to consider:
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a preclinical-stage monoclonal anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated C5 inhibitor in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of complement factor 5, or C5, for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. The company also has discovery-stage programs that are focused on the identification of small molecule therapeutics for patients with rare metabolic diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was incorporated in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporation operates as a subsidiary of Rallybio Holdings, LLC.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.